Edgewise Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview

Edgewise Therapeutics

06/08/2024 19:32

* Edgewise Therapeutics Inc  EWTX.OQ   EWTX.O  is expected
to show
no change in quarterly revenue when it reports  results on
August 8 (estimated) for the period ending January 1 0001
    * 
    * ​LSEG's mean analyst estimate for Edgewise Therapeutics
Inc is
for a loss of 34 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Edgewise
Therapeutics Inc is $32.00​, above​ its last closing price
of $15.89. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.39       -0.39      -0.33     Beat    15.8
 Jan. 1 2024   -0.41       -0.43      -0.47     Missed  -8.3
 Sep. 30 2023  -0.38       -0.40      -0.41     Missed  -3.5​
 Jun. 30 2023  -0.40       -0.40      -0.34     Beat    14.6
 ​​Mar.        -0.35       -0.36      -0.36     Met     0
 31 2023                                                
 Jan. 1 0001   -0.34       -0.34      -0.31     Beat    7.7​
 Jan. 1 0001   -0.35       -0.36      -0.34     Beat    4.5
 Jan. 1 0001   -0.33       -0.32      -0.32     Met     1.2
 This summary was machine generated August 6 at 18:31 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)